| Literature DB >> 31936688 |
Adeilso Bispo Dos Santos Junior1, Cinthia I Tamayose2, Marcelo J P Ferreira2, Mariana N Belchor1, Caroline R C Costa1, Marcos Antonio de Oliveira3, Marcos Hikari Toyama1.
Abstract
Bioaffinity capturing of molecules allows the discovery of bioactive compounds and decreases tEntities:
Keywords: anti-inflammatory; bioaffinity; natural compounds; ultrafiltration
Year: 2020 PMID: 31936688 PMCID: PMC7024236 DOI: 10.3390/molecules25020282
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Extracts screening against edematogenic activity of native secretory phospholipase A2 (sPLA2). All panels in this figure show the evaluation of extracts against sPLA2-induced edema with seven different extracts. (A) Effect of injected antivenom (AVn) 10 min after application of Cdt sPLA2, which significantly decreased the pro-inflammatory action induced by sPLA2; (B) hexanic (Hex), (D) ethyl acetate (AcOEt), (E) n-butanolic (n-BuOH), and (G) hydroethanolic (HE) extracts significantly reduced sPLA2-induced edema. The results strongly suggested that these extracts have a potential anti-inflammatory compound interacting with sPLA2. (C) Dichloromethane (DCM) and (F) methanol (MeOH) extracts demonstrated no significant effects on sPLA2 edematogenic activity. * significant differences relative to a standard. All analyses were performed using analysis of variance (ANOVA, p < 0.05), and each bar represent n = 5.
Figure 2Extract evaluation against enzymatic activity of native sPLA2. (A) Methanol (MeOH), (B) hexane (HEX), (C) dichloromethane (DCM), and (D) ethyl acetate (EtOAc) extracts exhibited inhibition of enzymatic activity. (E) n-butanol (n-BuOH) and (F) hydroethanolic extracts (HA) showed no significant inhibition of sPLA2 enzymatic activity. Error bars indicate the standard error of the mean (SEM); ∗ p ≤ 0.05 compared with the saline control.
Figure 3Reverse-phase HPLC analysis using an analytical Phenomenex C5 column where we incubated 10 μL of pure sPLA2 (1 mg/mL) with 10 μL of extract (0.1 mg/mL) at a ratio of 1:1 (v:v).
Figure 4Overlap of chromatograms from samples of methanol crude extract and MeOH 1C and MeOH 2C fractions obtained through the sPLA2 protein–ligand approach. Compounds were identified through NMR analysis as previously described [12,13]: (1) 3-CQA, 3-caffeoylquinic acid; (2) 5-CQA, 5-caffeoylquinic acid; (3) 4-CQA, 4-caffeoylquinic acid; (4) 3,4-dicaffeoylquinic acid; (5) 3,5-dicaffeoylquinic acid; (6) 4,5-dicaffeoylquinic acid; (7) 3,4,5-triCQA, 3,4,5-tricaffeoylquinic acid; and (8) hispidulin.
Figure 5Comparative analysis of 1C and 2C fractions from methanol extract incubated with sPLA2 on enzymatic (Figure 5A), edematogenic (Figure 5B), and myotoxic activities (Figure 5C) of isolated sPLA2. (A) Activity of the MeOH, MeOH 1C and 2C on phospholipase A2 enzymatic activity, where saline represents the control group. The results are expressed as a variation of enzymatic velocity Vo, and the error bars indicate the SEM. * Statistically significant differences (n = 5, p < 0.05) compared to native sPLA2. (B) show paw edema induced after the injection of sPLA2 and sPLA2 treated with MeOH extract and MeOH 1C and MeOH 2C, respectively, into the right paws of Swiss mice. Edema is expressed as volume in µL and measurements were performed after 30, 60, 120, 180, and 240 min. The error bars indicate the SEM of five experiments. * p < 0.05 compared to native sPLA2. (C) show the myonecrosis assay and the results are expressed as creatine kinase (CK) units of enzymatic activity per liter (U/L). The error bars indicate the SEM of five experiments. * p < 0.05 compared with native sPLA2.
Figure 6Analysis of the methyl and hydroxyl group on the protective function of hispidulin in inhibiting sPLA2-induced edema and myonecrosis and influences of these groups on the inhibition of sPLA2 enzymatic activity. (A) showed the structure of Hispidulin compared to Scutellarein (Scu) and Cirsimaritin (Cis). (B) Comparative analysis of His, Scu and Cis on phospholipase A2 enzymatic activity, where saline represents the control group. The results are expressed as a variation of enzymatic velocity Vo. (C) show paw edema induced after the injection of sPLA2 and sPLA2 treated with His, Cis and Scu, respectively, into the right paws of Swiss mice. Edema is expressed as volume in µL and measurements were performed after 30, 60, 120, 180, and 240 min. (D) show the myonecrosis assay and the results are expressed as creatine kinase (CK) units of enzymatic activity per liter (U/L). Error bars indicate the SEM; * p ≤ 0.05 compared with the saline control.
Figure 7Characterization of possible molecular interaction of His with sPLA2 from Crotalus durissus terrificus. (A) Investigation of the His–Ctd sPLA2 using reverse-phase HPLC. (B) Circular dichroism (CD) spectral profile data were acquired over the range of 185–280 nm. Ctd sPLA2 is represented by the gray line, Ctd sPLA2 + His by the dashed gray line, and His by the dotted gray line. The CD spectra are expressed in θ cm2/dmols. (C) Molecular modeling of hispidulin in the sPLA2 active site. The structure of Ctd SPLA2 is represented in dark blue (PDB: 2QOG) and the His molecule by sticks and lines with the atoms colored as follows: C, yellow; N, blue; O, red; and H, white (lines).
Figure 8Schematic to explain a possible molecular interaction of hispidulin on sPLA2.
Figure 9General scheme of screening natural compounds using secretory Phospholipase A2 as a target molecule for fishing for plant extract molecules and this method is intended to provide a tool to investigate potential molecules capable of modulating or inhibiting the pro-inflammatory actions induced by sPLA2 from plants or other organisms and to assess the importance of certain species among the biological diversity of a region as a potential producer of anti-inflammatory compounds.